Skip to main content

Table 1 Effects of test agents on baseline MSAP, HR and power density of vasomotor components of SAP spectrum in RVLM

From: Nontranscriptional activation of PI3K/Akt signaling mediates hypotensive effect following activation of estrogen receptor β in the rostral ventrolateral medulla of rats

 Treatment   Maximal changes in 
MSAP(mmHg) HR(bpm) Power Density(mmHg 2 )
aCSF +3.8 ± 0.5 +4.7 ± 0.9 +0.6 ± 0.7
ICI 182780 (0.25 pmol) +4.3 ± 0.4 +5.2 ± 0.6 +0.6 ± 0.6
ICI 182780 (0.5 pmol) +4.5 ± 0.5 +5.5 ± 0.3 +0.7 ± 0.5
R,R-THC (50 pmol) +4.6 ± 0.7 +5.7 ± 0.8 +0.8 ± 0.7
MPP (1 nmol) +5.3 ± 0.7 +5.1 ± 1.1 +0.8 ± 0.3
AMD (5 nmol) −4.2 ± 0.6 +2.4 ± 1.2 −0.6 ± 0.7
AMD (10 nmol) −4.5 ± 0.6 −3.4 ± 1.5 −0.6 ± 0.5
LY294002 (5 pmol ) +3.0 ± 0.7 −4.4 ± 1.0 +0.7 ± 0.6
Akt inhibitor (250 pmol) +2.8 ± 0.8 +4.0 ± 0.8 +0.8 ± 0.4
AdGFP (5 × 108 pfu) −4.1 ± 0.8 +5.1 ± 1.2 −0.7 ± 0.6
AdPTEN (5 × 108 pfu) −4.8 ± 1.1 +5.7 ± 1.0 −1.0 ± 0.5
ERα ASON (250 pmol) +5.5 ± 0.5 +5.5 ± 1.2 +0.6 ± 0.5
ERβ ASON (250 pmol) +5.4 ± 1.0 +4.6 ± 1.1 +0.7 ± 0.7
ERα SCR (250 pmol) +4.1 ± 0.8 +3.6 ± 1.0 +0.8 ± 0.7
ERβ SCR (250 pmol) +4.9 ± 0.7 −3.9 ± 0.6 +0.7 ± 0.5
  1. The baseline MSAP, HR and power density of vasomotor components of SAP spectrum were measured at 120 min, 24 h, or day 7 respectively, after microinjection bilaterally into RVLM of other test agents, ERα or ERβ ASON or SCR, or AdGFP or AdPTEN. All values are expressed as mean ± SEM; n = 6-7 animals per experimental group. Any significant differences (P < 0.05) were not detected between all the test agent groups and aCSF group in the Student’s t-test.